NasdaqGS - Nasdaq Real Time Price USD
ImmunityBio, Inc. (IBRX)
8.29 -0.45 (-5.15%)
At close: October 30 at 4:00:02 PM EDT
8.29 0.00 (0.00%)
After hours: October 30 at 7:55:48 PM EDT
Trade IBRX on Coinbase
Trading disclosure
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for certain activity generated through this link. Prices displayed are informational.
Learn moreChart Range Bar
Loading chart for IBRX
What's happening with IBRX?
Powered by Yahoo ScoutImmunityBio expanded ANKTIVA’s bladder-cancer approval and reported durable long-term results in BCG-unresponsive disease. Investors now await November results from the 366-patient QUILT-2.005 trial, which could support earlier use of ANKTIVA.
Powered by Yahoo Scout
- Previous Close
8.74 - Open
8.48 - Bid 6.25 x 200
- Ask 39.90 x 2600
- Day's Range
8.12 - 8.72 - 52 Week Range
1.95 - 12.43 - Volume
8,911,096 - Avg. Volume
11,481,468 - Market Cap (intraday)
8.786B - Beta (5Y Monthly) 0.03
- PE Ratio (TTM)
-- - EPS (TTM)
-0.96 - Earnings Date (est.) Nov 3, 2026
- Forward Dividend & Yield -- (0.00%)
- 1y Target Est
14.25 - Zacks Rating Bullish
Recent News
View More
Performance Overview
Trailing total returns as of 10/30/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
IBRX
318.69%
S&P 500 (^GSPC)
10.73%
1-Year Return
IBRX
251.27%
S&P 500 (^GSPC)
11.11%
3-Year Return
IBRX
169.16%
S&P 500 (^GSPC)
81.91%
5-Year Return
IBRX
5.87%
S&P 500 (^GSPC)
64.59%
Earnings Trends
View MoreAnalyst Insights
View MoreStatistics
View MoreValuation Measures
As of 10/30/2026
Market Cap
8.78B
Enterprise Value
9.23B
Trailing P/E
--
Forward P/E
82.80
PEG Ratio (current)
--
Price/Sales (ttm)
50.13
Price/Book (mrq)
--
Enterprise Value/Revenue
55.68
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-30.54%
Return on Equity (ttm)
--
Revenue (ttm)
165.79M
Net Income Avi to Common (ttm)
-992.36M
Diluted EPS (ttm)
-0.96
Balance Sheet and Cash Flow
Total Cash (mrq)
357.37M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-186.56M
Compare
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Mkt Cap undefined -
Industry -
Mkt Cap undefined -
Industry -
Mkt Cap undefined -
Industry -
Mkt Cap undefined -
Industry -
Mkt Cap undefined -
Industry -
Mkt Cap undefined -
Industry -
Mkt Cap undefined -
Industry -
Company Insights
Fair Value
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected. Learn more
Dividend Score
The distribution of earnings a company pays back to its shareholders based off the company’s profits. Usually paid out on a quarterly basis in the form of cash or additional stocks.
Hiring Score
A company’s hiring trends in key indicators can indicate how well the company is doing in terms of growing the company and where they are currently prioritizing.
Insider Sentiment Score
Vicker’s Insider Sentiment provides insights into trades made by insiders. This can be used to gain valuable insights and as a reflection of the prospect of the company based on insider trading.